Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of BioCentury Extra, The Daily News: Financial News

BioCentury Extra, The Daily News Current Issue
  • FINANCIAL NEWS: Evoke files for IPO

    Gastrointestinal disease company Evoke Pharma Inc. (San Diego, Calif.) filed to raise up to $23.9 million in an IPO on NASDAQ underwritten by Aegis Capital. Next half, the company plans to start a Phase III trial of EVK…

    Published on 5/24/2013
  • FINANCIAL NEWS: Prosensa files for IPO

    Prosensa B.V. (Leiden, the Netherlands) filed to raise up to $60 million in an IPO on NASDAQ underwritten by JPMorgan; Citigroup; Leerink; Wedbush; and KBC Securities. Last month, partner GlaxoSmithKline plc (LSE:GSK; …

    Published on 5/24/2013
  • FINANCIAL NEWS: ReproCell planning IPO in Japan

    Stem cell company ReproCell Inc. (Yokohama, Japan) filed to sell 642,000 shares in an IPO on the JASDAQ Growth Market of the Osaka Securities Exchange. The offer is underwritten by SMBC Nikko Securities and seven other …

    Published on 5/24/2013
  • FINANCIAL NEWS: Valeant up on Bausch + Lomb takeout rumors

    Shares of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) jumped C$10.18 (13%) to C$87.02 in Toronto and $9.80 (13%) to $84.47 in New York on Friday after the Wall Street Journal reported the company is …

    Published on 5/24/2013
  • FINANCIAL NEWS: AnGes raises $11.2 million

    Japanese gene therapy company AnGes MG Inc. (Tokyo:4563) raised Y1.1 billion ($11.2 million) after Merrill Lynch Japan Securities exercised 4,000 stock acquisition rights at Y287,100. Each right entitles Merrill to …

    Published on 5/23/2013
  • FINANCIAL NEWS: Apricus raises $17.1M in follow-on

    Apricus Biosciences Inc. (NASDAQ:APRI) raised $17.1 million through the sale of 6 million shares at $2.85 in a follow-on underwritten by Lazard; Roth Capital Partners; and Cantor Fitzgerald. The underwriters also …

    Published on 5/23/2013
  • FINANCIAL NEWS: Cardeas raises $34M in series B

    Infectious disease company Cardeas Pharma Corp. (Seattle, Wash.) raised $34 million in a series B round led by new investor H.I.G. BioVentures. Existing investors Novo A/S; Avalon Ventures; Devon Park Bioventures; and …

    Published on 5/23/2013
  • FINANCIAL NEWS: Jennerex raises $21.6 million

    Cancer company Jennerex Biotherapeutics Inc. (San Francisco, Calif.) raised $21.6 million in an undisclosed venture round from undisclosed investors. The biotech's Pexa-Vec (JX-594) is in the Phase IIb TRANSVERSE trial …

    Published on 5/23/2013
  • FINANCIAL NEWS: PeptiDream raises IPO range

    PeptiDream Inc. (Tokyo, Japan) amended its IPO and now plans to sell 1.7 million shares at Y1,920-Y2,500 in an IPO on the Tokyo Stock Exchange's market of the high-growth and emerging stocks (Mothers). At the Y2,210 mid…

    Published on 5/23/2013
  • FINANCIAL NEWS: Ironwood raises $136.5M, NPS raises $87.2M

    Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) raised $136.5 million and NPS Pharmaceuticals Inc. (NASDAQ:NPSP) raised $87.2 million in follow-ons on Wednesday. Ironwood sold 10.5 million shares at $13 in a follow-on …

    Published on 5/22/2013
  • FINANCIAL NEWS: Portola, Alcobra price IPOs

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA) raised $122.1 million and Alcobra Ltd. (NASDAQ:ADHD) raised $25 million after pricing their IPOs on Wednesday. Portola sold 8.4 million shares at $14.50, the mid-point of its …

    Published on 5/22/2013
  • FINANCIAL NEWS: Epizyme sets IPO range

    Cancer company Epizyme Inc. (Cambridge, Mass.) amended its IPO and said it plans to sell 4.3 million shares at $13-$15. At the $14 mid-point, Epizyme would raise $60 million and be valued at $375 million. Earlier this …

    Published on 5/21/2013
  • FINANCIAL NEWS: France launches rare disease fund

    The French government's Fonds National d'Amorcage and the not-for-profit AFM-Telethon launched a seed fund to invest in biotherapeutics for rare diseases. The new fund, which will be managed by CDC Enterprises launched …

    Published on 5/21/2013
  • FINANCIAL NEWS: Merck to buy back $5B in shares from Goldman

    Merck & Co. Inc. (NYSE:MRK) said it will repurchase about $5 billion in stock, or about 99.5 million shares, from Goldman Sachs under an accelerated share repurchase program. The program is slated to be completed by Nov…

    Published on 5/21/2013
  • FINANCIAL NEWS: Athyrium, Neuberger close $507M fund

    Athyrium Capital Management and partner Neuberger Berman closed a life sciences private credit fund, Athyrium Opportunities Fund L.P., at $507 million, well above the original target of $350 million. The fund, which the…

    Published on 5/20/2013
  • FINANCIAL NEWS: Effector raises $45M in tranched series A

    Effector Therapeutics Inc. (San Diego, Calif.) raised $45 million in a tranched series A round co-led by U.S. Venture Partners; Abingworth; Novartis Venture Funds; and SR One. Astellas Venture Management; Osage …

    Published on 5/20/2013
  • FINANCIAL NEWS: Ironwood, NPS planning follow-ons

    Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and NPS Pharmaceuticals Inc. (NASDAQ:NPSP) both announced plans late Monday to raise money in follow-ons. Ironwood proposed to sell 10.5 million shares in a follow-on …

    Published on 5/20/2013
  • FINANCIAL NEWS: Karyopharm raises $48.2 million in series B

    Cancer company Karyopharm Therapeutics Inc. (Natick, Mass.) raised $48.2 million in a series B round led by an undisclosed private investor. New investor Delphi Ventures and additional undisclosed investors participated…

    Published on 5/20/2013
  • FINANCIAL NEWS: NanoString files for IPO

    Diagnostics company NanoString Technologies Inc. (Seattle, Wash.) filed to raise up to $86.3 million in an IPO underwritten by JPMorgan; Morgan Stanley; Leerink; and Baird. Earlier this year, NanoString launched its …

    Published on 5/20/2013
  • FINANCIAL NEWS: Kamada amends NASDAQ offering

    Kamada Ltd. (Tel Aviv:KMDA) said it now plans to raise about $60 million through the sale and listing of 5.6 million shares on NASDAQ in a follow-on. The company also added RBC Capital Markets; Oppenheimer; and Chardan …

    Published on 5/17/2013
  • FINANCIAL NEWS: Ambit raises $65 million in IPO

    Ambit Biosciences Corp. (NASDAQ:AMBI) was off $0.61 to $7.39 in its first day of trading on Thursday after the company raised $65 million through the sale of 8.1 million shares at $8 in an IPO. Citigroup; Leerink; BMO …

    Published on 5/16/2013
  • FINANCIAL NEWS: Cyclacel, Stemline raise combined $80M in follow-ons

    Cancer companies Stemline Therapeutics Inc. (NASDAQ:STML) and Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) raised a combined $80 million in follow-ons on Thursday. Stemline raised $60 million in a bumped-up offering …

    Published on 5/16/2013
  • FINANCIAL NEWS: Merck KGaA expands venture fund to EUR 100 million

    Merck KGaA (Xetra:MRK) expanded to EUR 100 million ($129.7 million) its MS Ventures fund. The strategic fund was formed in 2009 with EUR 40 million ($51.9 million) to invest in biotech startups working in areas …

    Published on 5/16/2013
  • FINANCIAL NEWS: PTC files for IPO

    PTC Therapeutics Inc. (South Plainfield, N.J.) filed to raise up to $85 million in an IPO underwritten by JPMorgan; Credit Suisse; Cowen; and Wedbush. PTC, which raised $60 million in a venture round in March, pulled …

    Published on 5/16/2013
  • FINANCIAL NEWS: Vivus raises $220M in note offering

    Vivus Inc. (NASDAQ:VVUS) raised $220 million through the sale of 4.5% unsecured senior convertible notes due May 1, 2020. The notes initially convert at $14.86, which is a 9% premium to Vivus' close of $13.59 on Tuesday…

    Published on 5/16/2013

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

The Daily Extra

Concise and authoritative news for biotech and pharma, written each business day by BioCentury’s senior editors and analysts.


Find out how to get your biopharma daily news update.